These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20091252)

  • 1. [Limits and scopes of invasive risk stratification. Do we still need programmed ventricular stimulation?].
    Rolf S; Haverkamp W
    Herz; 2009 Nov; 34(7):528-38. PubMed ID: 20091252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of electrophysiology study in risk stratification of sudden cardiac death.
    Thomas KE; Josephson ME
    Prog Cardiovasc Dis; 2008; 51(2):97-105. PubMed ID: 18774009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and documented sustained ventricular tachyarrhythmias: inducibility and prognostic value in 102 patients.
    Chen X; Shenasa M; Borggrefe M; Block M; Hindricks G; Martinez-Rubio A; Haverkamp W; Willems S; Böcker D; Mäkijärvi M
    Eur Heart J; 1994 Jan; 15(1):76-82. PubMed ID: 8174587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy.
    Perazzolo Marra M; De Lazzari M; Zorzi A; Migliore F; Zilio F; Calore C; Vettor G; Tona F; Tarantini G; Cacciavillani L; Corbetti F; Giorgi B; Miotto D; Thiene G; Basso C; Iliceto S; Corrado D
    Heart Rhythm; 2014 May; 11(5):856-63. PubMed ID: 24440822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia.
    Grimm W; Hoffmann J; Menz V; Luck K; Maisch B
    J Am Coll Cardiol; 1998 Sep; 32(3):739-45. PubMed ID: 9741521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Ventricular Stimulation as an Additional Primary Prevention Risk Stratification Tool in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational Study.
    Gasperetti A; Carrick RT; Costa S; Compagnucci P; Bosman LP; Chivulescu M; Tichnell C; Murray B; Tandri H; Tadros R; Rivard L; van den Berg MP; Zeppenfeld K; Wilde AAM; Pompilio G; Carbucicchio C; Dello Russo A; Casella M; Svensson A; Brunckhorst CB; van Tintelen JP; Platonov PG; Haugaa KH; Duru F; Te Riele ASJM; Khairy P; Tondo C; Calkins H; James CA; Saguner AM; Cadrin-Tourigny J
    Circulation; 2022 Nov; 146(19):1434-1443. PubMed ID: 36205131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
    BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive markers for sudden cardiac death risk stratification in dilated cardiomyopathy.
    Pooranachandran V; Nicolson W; Vali Z; Li X; Ng GA
    Heart; 2022 Jun; 108(13):998-1004. PubMed ID: 34670824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator.
    Park YM
    Korean J Intern Med; 2023 Jan; 38(1):7-15. PubMed ID: 36353786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
    Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
    Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of ventricular arrhythmias using cardiovascular magnetic resonance.
    Mavrogeni S; Petrou E; Kolovou G; Theodorakis G; Iliodromitis E
    Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):518-25. PubMed ID: 23324829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy: clinical presentation, risk stratification and results of long-term follow-up.
    Pezawas T; Stix G; Kastner J; Schneider B; Wolzt M; Schmidinger H
    Int J Cardiol; 2006 Mar; 107(3):360-8. PubMed ID: 16503259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic implantable cardioverter defibrillator trials: MUSTT, MADIT, and beyond. Multicenter Unsustained Tachycardia Trial. Multicenter Automatic Defibrillator Implantation Trial.
    Prystowsky EN; Nisam S
    Am J Cardiol; 2000 Dec; 86(11):1214-5, A5. PubMed ID: 11090794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of repeat programmed ventricular stimulation at electrophysiology study for arrhythmia prediction after acute myocardial infarction.
    Zaman S; Narayan A; Thiagalingam A; Sivagangabalan G; Thomas S; Ross DL; Kovoor P
    Pacing Clin Electrophysiol; 2014 Jul; 37(7):795-802. PubMed ID: 24666010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained polymorphic arrhythmias induced by programmed ventricular stimulation have prognostic value in patients receiving defibrillators.
    Greenberg SL; Mauricio Sánchez J; Cooper JA; Cain ME; Chen J; Gleva MJ; Lindsay BD; Smith TW; Faddis MN
    Pacing Clin Electrophysiol; 2007 Sep; 30(9):1067-75. PubMed ID: 17725748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
    Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy.
    Wang W; Lian Z; Rowin EJ; Maron BJ; Maron MS; Link MS
    Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28314849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening and therapy for patients with nonsustained ventricular tachycardia.
    Prystowsky EN
    Am J Cardiol; 2000 Nov; 86(9A):34K-39K. PubMed ID: 11084098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.